Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, September 2, 2021
Information
Tags: 
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, GIST, Cancer, NASDAQ, LinkedIn, Conference, Pharmaceutical industry
Geotags: 
United States, Massachusetts, CHINA, AUSTRALIA, HONG KONG, CANADA
⚠ generated by AI ↴
Organisation: 
DECIPHERA PHARMACEUTICALS
Summary
Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET.
  • A live webcast of the event will be available on the Events and Presentations page in the Investors section of the Companys website at https://investors.deciphera.com/events-presentations .
  • A replay of the webcast will be archived on the Companys website for 90 days following the presentation.
  • Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, China, and Hong Kong. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Copyright: 
Copyright Business Wire 2021